Literature DB >> 18174778

Risk-based classification of hypertension and the role of combination therapy.

Matthew R Weir1.   

Abstract

The recognition of a continuous relationship between elevated blood pressure (BP) and cardiovascular risk has influenced national and international guidelines for the classification, prevention, and management of hypertension. The most recent report (2003) of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure uses BP thresholds to define categories of normal, prehypertension, and hypertension. A new definition proposed by the Hypertension Writing Group in 2005 offers an approach to diagnosis and management based on global or total risk. Thus, even in the absence of sustained elevations in BP, patients may have a moderate to high risk of vascular events due to the presence of additional cardiovascular risk factors, disease markers, and target organ damage. The 2007 European guidelines continue to classify hypertension based on cutoffs while also placing emphasis on multivariate formulations for cardiovascular risk assessment and goals of therapy. All 3 sets of guidelines acknowledge the necessity of using > or =2 antihypertensive agents to attain BP goals in many patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18174778      PMCID: PMC8109914          DOI: 10.1111/j.1524-6175.2007.08134.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  69 in total

Review 1.  The vasodilatory beta-blockers.

Authors:  Michala E Pedersen; John R Cockcroft
Journal:  Curr Hypertens Rep       Date:  2007-08       Impact factor: 5.369

2.  Impact of high-normal blood pressure on the risk of cardiovascular disease.

Authors:  R S Vasan; M G Larson; E P Leip; J C Evans; C J O'Donnell; W B Kannel; D Levy
Journal:  N Engl J Med       Date:  2001-11-01       Impact factor: 91.245

3.  A comparison of the efficacy and safety of a beta-blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks.

Authors:  E Saunders; M R Weir; B W Kong; J Hollifield; J Gray; V Vertes; J R Sowers; M B Zemel; C Curry; J Schoenberger
Journal:  Arch Intern Med       Date:  1990-08

4.  Prevalence and trends of prehypertension and hypertension in United States: National Health and Nutrition Examination Surveys 1976 to 2000.

Authors:  Adnan I Qureshi; M Fareed K Suri; Jawad F Kirmani; Afshin A Divani
Journal:  Med Sci Monit       Date:  2005-08-26

5.  Angiotensin receptor-1 blocker inhibits atherosclerotic changes and endothelial disruption of the aortic valve in hypercholesterolemic rabbits.

Authors:  Kumiko Arishiro; Masaaki Hoshiga; Nobuyuki Negoro; Denan Jin; Shinji Takai; Mizuo Miyazaki; Tadashi Ishihara; Toshiaki Hanafusa
Journal:  J Am Coll Cardiol       Date:  2007-03-21       Impact factor: 24.094

6.  Effects of "newer" and "older" antihypertensive drugs on hemorrheological, platelet, and endothelial factors. A substudy of the Anglo-Scandinavian Cardiac Outcomes Trial.

Authors:  Charles G C Spencer; Dirk C Felmeden; Andrew D Blann; Gregory Y H Lip
Journal:  Am J Hypertens       Date:  2007-06       Impact factor: 2.689

7.  Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE).

Authors:  Vasilios Papademetriou; Csaba Farsang; Dag Elmfeldt; Albert Hofman; Hans Lithell; Bertil Olofsson; Ingmar Skoog; Peter Trenkwalder; Alberto Zanchetti
Journal:  J Am Coll Cardiol       Date:  2004-09-15       Impact factor: 24.094

8.  Effects of carvedilol versus metoprolol on endothelial function and oxidative stress in patients with type 2 diabetes mellitus.

Authors:  Alan J Bank; Aaron S Kelly; Andrea M Thelen; Daniel R Kaiser; J Michael Gonzalez-Campoy
Journal:  Am J Hypertens       Date:  2007-07       Impact factor: 2.689

9.  The effects of nonsteroidal anti-inflammatory drugs on blood pressures of patients with hypertension controlled by verapamil.

Authors:  M C Houston; M Weir; J Gray; D Ginsberg; C Szeto; P M Kaihlenen; D Sugimoto; M Runde; M Lefkowitz
Journal:  Arch Intern Med       Date:  1995-05-22

10.  2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).

Authors:  Giuseppe Mancia; Robert Fagard; Krzysztof Narkiewicz; Josep Redon; Alberto Zanchetti; Michael Böhm; Thierry Christiaens; Renata Cifkova; Guy De Backer; Anna Dominiczak; Maurizio Galderisi; Diederick E Grobbee; Tiny Jaarsma; Paulus Kirchhof; Sverre E Kjeldsen; Stéphane Laurent; Athanasios J Manolis; Peter M Nilsson; Luis Miguel Ruilope; Roland E Schmieder; Per Anton Sirnes; Peter Sleight; Margus Viigimaa; Bernard Waeber; Faiez Zannad; Josep Redon; Anna Dominiczak; Krzysztof Narkiewicz; Peter M Nilsson; Michel Burnier; Margus Viigimaa; Ettore Ambrosioni; Mark Caufield; Antonio Coca; Michael Hecht Olsen; Roland E Schmieder; Costas Tsioufis; Philippe van de Borne; Jose Luis Zamorano; Stephan Achenbach; Helmut Baumgartner; Jeroen J Bax; Héctor Bueno; Veronica Dean; Christi Deaton; Cetin Erol; Robert Fagard; Roberto Ferrari; David Hasdai; Arno W Hoes; Paulus Kirchhof; Juhani Knuuti; Philippe Kolh; Patrizio Lancellotti; Ales Linhart; Petros Nihoyannopoulos; Massimo F Piepoli; Piotr Ponikowski; Per Anton Sirnes; Juan Luis Tamargo; Michal Tendera; Adam Torbicki; William Wijns; Stephan Windecker; Denis L Clement; Antonio Coca; Thierry C Gillebert; Michal Tendera; Enrico Agabiti Rosei; Ettore Ambrosioni; Stefan D Anker; Johann Bauersachs; Jana Brguljan Hitij; Mark Caulfield; Marc De Buyzere; Sabina De Geest; Geneviève Anne Derumeaux; Serap Erdine; Csaba Farsang; Christian Funck-Brentano; Vjekoslav Gerc; Giuseppe Germano; Stephan Gielen; Herman Haller; Arno W Hoes; Jens Jordan; Thomas Kahan; Michel Komajda; Dragan Lovic; Heiko Mahrholdt; Michael Hecht Olsen; Jan Ostergren; Gianfranco Parati; Joep Perk; Jorge Polonia; Bogdan A Popescu; Zeljko Reiner; Lars Rydén; Yuriy Sirenko; Alice Stanton; Harry Struijker-Boudier; Costas Tsioufis; Philippe van de Borne; Charalambos Vlachopoulos; Massimo Volpe; David A Wood
Journal:  Eur Heart J       Date:  2013-06-14       Impact factor: 29.983

View more
  4 in total

Review 1.  Appetite suppressants, cardiac valve disease and combination pharmacotherapy.

Authors:  Richard B Rothman; Michael H Baumann
Journal:  Am J Ther       Date:  2009 Jul-Aug       Impact factor: 2.688

2.  Angiotensin II Blockade and Total Cardiovascular Risk : Beyond Blood Pressure Reduction.

Authors:  Francesco Cipollone; Sara Di Fabio; Marco Bucci; Giancarlo Cicolini; Andrea Mezzetti
Journal:  High Blood Press Cardiovasc Prev       Date:  2013-01-22

Review 3.  Prognostic significance of the morning blood pressure surge in clinical practice: a systematic review.

Authors:  James Peter Sheppard; James Hodgkinson; Richard Riley; Una Martin; Susan Bayliss; Richard J McManus
Journal:  Am J Hypertens       Date:  2014-10-14       Impact factor: 2.689

4.  A randomized trial of the efficacy and safety of azilsartan medoxomil combined with chlorthalidone.

Authors:  Michael A Weber; Peter Sever; Attila Juhasz; Andrew Roberts; Charlie Cao
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2018 Jul-Sep       Impact factor: 1.636

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.